Gerhard Mayr - UCB SA Insider

UCBJY -- USA Stock  

USD 42.80  0.00  0.00%

Mr. Gerhard N. Mayr has served as NonExecutive Chairman of the Board of U C B S.A. since May 2012. He served as NonExecutive Independent Director of the Company between June 14, 2005 and May 2012. He received a Master degree in Chemical Engineering from the Swiss Federal Institute of Technology in 1969, and a MBA degree from Stanford University in 1972. In March 2004, he retired as Executive Vice President of pharmaceutical operations at Eli Lilly Company after 32 years of service
Age: 68  Chairman Since 2012      
32 2 559 99 99
Mayr is Member of the Board of Lonza Group Ltd ., Member of the Board of the Vienna Science, Research and Technology Foundation and Member of the Board of Project Hope, United States . He is Member of the circle of patrons of INSEAD Business School . He was previously Member of the board of Alcon, Inc

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.83 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology ? Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

Stock Performance Indicators

Current Sentiment - UCBJY

UCB SA Investor Sentiment
Macroaxis portfolio users are unemotional in their outlook on investing in UCB SA. What is your outlook on investing in UCB SA? Are you bullish or bearish?
50% Bullish
50% Bearish

Also Currentnly Active

Purchased over 500 shares of
few days ago
Traded for 6.08
Purchased over 500 shares of
few days ago
Traded for 6.08
Purchased over 100 shares of
few days ago
Traded for 2.17
Also please take a look at World Market Map. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.